Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice

AIDS. 2015 Oct 23;29(16):2155-9. doi: 10.1097/QAD.0000000000000819.

Abstract

Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-HIV Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Cyclohexanes / therapeutic use*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / isolation & purification
  • Humans
  • Male
  • Maraviroc
  • Off-Label Use*
  • Retrospective Studies
  • Salvage Therapy / methods
  • Treatment Outcome
  • Triazoles / therapeutic use*
  • Viral Load
  • Young Adult

Substances

  • Anti-HIV Agents
  • Cyclohexanes
  • Triazoles
  • Maraviroc